Dersimelagon - Mitsubishi Tanabe Pharma
Alternative Names: [14C] MT-7117; Dersimelagon; MT-7117; MT-7117-MBLatest Information Update: 22 Jul 2024
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Carboxylic acids; Cyclopentanes; Fluorinated hydrocarbons; Phenyl ethers; Piperidines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Erythropoietic protoporphyria
- Phase II Diffuse scleroderma
- No development reported Autoimmune disorders
Most Recent Events
- 12 Jun 2024 Efficacy data from a phase II trial in Diffuse scleroderma presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 14 Feb 2024 Mitsubishi Tanabe Pharma America completes a phase II trial in Diffuse scleroderma (In the elderly, In adults) in USA, Belgium, Canada, Germany, Italy, Spain, Poland and the United Kingdom (PO) (NCT04440592) (EudraCT2020-000134-17)
- 11 Dec 2023 Phase-III clinical trials in Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA (PO) (NCT06144840)